These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38546676)

  • 1. Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study.
    Shen KN; Gao YJ; Chang L; Zhang L; Cao XX; Tian Z; Wang YN; Zhou DB; Li J
    Haematologica; 2024 Jul; 109(7):2355-2358. PubMed ID: 38546676
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures.
    Zanwar S; Gertz MA; Muchtar E; Buadi FK; Kourelis T; Gonsalves W; Go RS; Hayman S; Kapoor P; Binder M; Cook J; Dingli D; Leung N; Lin Y; Warsame R; Fonder A; Hobbs M; Hwa YL; Kyle RA; Rajkumar SV; Kumar S; Dispenzieri A
    Leukemia; 2024 Jun; 38(6):1423-1426. PubMed ID: 38594348
    [No Abstract]   [Full Text] [Related]  

  • 3. A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.
    Bellofiore C; Benvenuti P; Mina R; Basset M; Foli A; Nanci M; Nuvolone M; Guida G; Attanasio A; Mussinelli R; Mangiacavalli S; Cartia CS; Masoni V; Palumbo M; Cani L; Oliva S; Consoli U; Conticello C; Di Raimondo F; Arcaini L; Bringhen S; Merlini G; Palladini G; Milani P
    Hematol Oncol; 2024 Jul; 42(4):e3289. PubMed ID: 38824453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response rates to second-line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib-based regime.
    Bomsztyk J; Ravichandran S; Khwaja J; Cohen O; Rauf MU; Foard D; Martinez-Naharro A; Venneri L; Whelan C; Fontana M; Hawkins PN; Gillmore J; Lachmann H; Mahmood S; Wechalekar AD
    Br J Haematol; 2024 Jul; 205(1):138-145. PubMed ID: 38840512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
    Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
    N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
    Palladini G; Kastritis E; Maurer MS; Zonder J; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Bumma N; Kaufman JL; Medvedova E; Kovacsovics T; Rosenzweig M; Sanchorawala V; Qin X; Vasey SY; Weiss BM; Vermeulen J; Merlini G; Comenzo RL
    Blood; 2020 Jul; 136(1):71-80. PubMed ID: 32244252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
    Oubari S; Hegenbart U; Schoder R; Steinhardt M; Papathanasiou M; Rassaf T; Thimm A; Hagenacker T; Naser E; Duhrsen U; Reinhardt HC; Kortum M; Agis H; Schonland S; Carpinteiro A
    Haematologica; 2024 Jan; 109(1):220-230. PubMed ID: 37439344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Blair HA
    Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.
    Kawano Y; Hata H; Takashio S; Tsujita K; Ueda M; Matsuoka M
    Br J Haematol; 2022 Aug; 198(3):e38-e41. PubMed ID: 35524546
    [No Abstract]   [Full Text] [Related]  

  • 10. Response matters in light chain amyloidosis, whatever it takes.
    Palladini G; Milani P
    Br J Haematol; 2024 Jul; 205(1):25-27. PubMed ID: 38842142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.
    Kimmich CR; Terzer T; Benner A; Hansen T; Carpinteiro A; Dittrich T; Veelken K; Jauch A; Huhn S; Basset M; Goldschmidt H; Müller-Tidow C; Schönland SO; Hegenbart U
    Am J Hematol; 2021 Jul; 96(7):E253-E257. PubMed ID: 33844864
    [No Abstract]   [Full Text] [Related]  

  • 12. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Kennedy VE; Natsuhara K; Maringanti SA; Shah ND; Arora S; Wolf J; Martin TG; Aras MA; Chung A; Wong SW
    Curr Probl Cancer; 2023 Jun; 47(3):100953. PubMed ID: 36807996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
    Moreau P; Hulin C; Perrot A; Arnulf B; Belhadj K; Benboubker L; Béné MC; Zweegman S; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Mohty M; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Macro M; Orsini-Piocelle F; Roussel M; Stoppa AM; van de Donk NWCJ; Wuillème S; Broijl A; Touzeau C; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Offner F; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Krevvata M; Zhang K; de Boer C; Vara S; Kampfenkel T; Vanquickelberghe V; Vermeulen J; Avet-Loiseau H; Sonneveld P
    Lancet Oncol; 2021 Oct; 22(10):1378-1390. PubMed ID: 34529931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
    Nooka AK; Kaufman JL; Rodriguez C; Jakubowiak A; Efebera Y; Reeves B; Wildes TM; Holstein SA; Anderson LD; Badros A; Shune L; Chari A; Pei H; Cortoos A; Patel S; Lin TS; Voorhees PM; Usmani SZ; Richardson PG
    Br J Haematol; 2024 Jun; 204(6):2227-2232. PubMed ID: 38504552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
    Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Qi M; Schecter J; Amin H; Qin X; Deraedt W; Ahmadi T; Spencer A; Sonneveld P;
    N Engl J Med; 2016 Aug; 375(8):754-66. PubMed ID: 27557302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
    Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
    Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.
    Kastritis E; Leleu X; Arnulf B; Zamagni E; Cibeira MT; Kwok F; Mollee P; Hájek R; Moreau P; Jaccard A; Schönland SO; Filshie R; Nicolas-Virelizier E; Augustson B; Mateos MV; Wechalekar A; Hachulla E; Milani P; Dimopoulos MA; Fermand JP; Foli A; Gavriatopoulou M; Klersy C; Palumbo A; Sonneveld P; Johnsen HE; Merlini G; Palladini G
    J Clin Oncol; 2020 Oct; 38(28):3252-3260. PubMed ID: 32730181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma.
    Elsada A; Adler AI
    Lancet Oncol; 2019 May; 20(5):619-620. PubMed ID: 30981602
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
    Bahlis NJ; Baz R; Harrison SJ; Quach H; Ho SJ; Vangsted AJ; Plesner T; Moreau P; Gibbs SD; Coppola S; Yang X; Al Masud A; Ross JA; Bueno O; Kaufman JL
    J Clin Oncol; 2021 Nov; 39(32):3602-3612. PubMed ID: 34388020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.
    Kastritis E; Dialoupi I; Gavriatopoulou M; Roussou M; Kanellias N; Fotiou D; Ntanasis-Stathopoulos I; Papadopoulou E; Ziogas DC; Stamatelopoulos K; Manios E; Ntalianis A; Eleutherakis-Papaiakovou E; Papanikolaou A; Migkou M; Papanota AM; Gakiopoulou H; Psimenou E; Tselegkidi MI; Tsitsilonis O; Kostopoulos I; Terpos E; Dimopoulos MA
    Blood Adv; 2019 Oct; 3(20):3002-3009. PubMed ID: 31648323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.